Novavax, Inc.
NVAX - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.66B
Close$
$24.78
160.1% upside
Current Fair Value
160.1% upsideUndervalued by 160.1% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $1.66 Billion |
|---|---|
| Enterprise Value | $1.86 Billion |
| Earnings per Share | $2.72 |
| Beta | 2.44 |
| Outstanding Shares | 164,574,000 |
Return
| Return on Equity | 129.90% |
|---|---|
| Return on Assets | -25.92% |
| Return on Invested Capital | -29.16% |
Valuation & Multiples
| P/E Ratio | -6.63 |
|---|---|
| PEG | 4.42 |
| Price to Sales | 4.77 |
| Price to Book Ratio | -4.77 |
| Enterprise Value to Revenue | 4.48 |
| Enterprise Value to EBIT | -10.18 |
| Enterprise Value to Net Income | -8 |
| Total Debt to Enterprise | 0.21 |
| Debt to Equity | -2.01 |
Revenue Sources
No data
Last Earnings Call
Report Date
August 6, 2026
EPS Estimate
$-0.38
Consensus analyst estimateRevenue Estimate
$52.51 M
Consensus analyst estimateNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
$-0.35
Consensus analyst estimateRevenue Estimate
$50.42 M
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.0000▼ 121.84% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 8.71%▼ 64.02% |
|---|---|
| Total Invested | $155.02M▼ 86.14% |
| Investors Holding | 56▼ 243.00% |
About Novavax, Inc.
749 employees
CEO: Stanley Erck
Novavax, Inc., a biotechnology company, engages in the discovery, development, and commercialization of vaccines to prevent serious infectious diseases in the United States, Europe, and internationally. The company commercializes Nuvaxov...